Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

by NASDAQ Market News December 9, 2021

NASDAQ Market News
Click here to email author

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy

LiVDerm to Host Leaders in Pediatric Dermatology at MOPD’s 30th Anniversary Symposium

Ads